ZLAB
Zai Lab LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.57B
P/E Ratio
—
EPS
$-1.60
Beta
0.86
52W High
$44.34
52W Low
$15.96
50-Day MA
$20.03
200-Day MA
$24.98
Dividend Yield
—
Profit Margin
-38.20%
Forward P/E
—
PEG Ratio
—
About Zai Lab Ltd
Zai Lab Limited, a biopharmaceutical company, discovers, licenses, develops and markets therapies to treat cancer, autoimmune and infectious diseases in China. The company is headquartered in Shanghai, China.
Fundamentals
| Revenue (TTM) | $460.16M |
| Gross Profit (TTM) | $48.17M |
| EBITDA | $-214.42M |
| Operating Margin | -54.40% |
| Return on Equity | -22.60% |
| Return on Assets | -12.20% |
| Revenue/Share (TTM) | $4.20 |
| Book Value | $6.47 |
| Price-to-Book | 3.59 |
| Price-to-Sales (TTM) | 5.59 |
| EV/Revenue | 4.494 |
| EV/EBITDA | -2.35 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 17.00% |
| Shares Outstanding | $112.67M |
| Float | $959.93M |
| % Insiders | 1.90% |
| % Institutions | 34.64% |
Historical Volatility
HV 10-Day
66.83%
HV 20-Day
57.62%
HV 30-Day
55.32%
HV 60-Day
52.26%
HV Rank
51.6%
Volatility is currently expanding
Analyst Ratings
Consensus ($35.16 target)
2
Strong Buy8
Buy1
HoldData last updated: 4/27/2026